Ruxolitinib for preventing relapse of Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis
Pediatrics International · 2025-01 · 67 (1)
DOI: 10.1111/ped.70032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatrics International, online erschienen am 23.03.2025. Verfasst von Eri Okura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
- Department of Transfusion, Shinshu University Hospital, Matsumoto, Japan.
ORCID-Profile: Kenichi Sakamoto, Yuta Maruyama, Koichi Hirabayashi, Shoji Saito, Ryu Yanagisawa, Yozo Nakazawa
Zitieren
APA
Okura, E., Sakamoto, K., Maruyama, Y., Hirabayashi, K., Saito, S., Yanagisawa, R., & Nakazawa, Y. (2025). Ruxolitinib for preventing relapse of Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis. Pediatrics International, 67(1). https://doi.org/10.1111/ped.70032
Vancouver
Okura E, Sakamoto K, Maruyama Y, Hirabayashi K, Saito S, Yanagisawa R, et al. Ruxolitinib for preventing relapse of Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis. Pediatrics International. 2025;67(1). doi:10.1111/ped.70032
BibTeX
@article{Okura2025,
author = {Okura, Eri and Sakamoto, Kenichi and Maruyama, Yuta and Hirabayashi, Koichi and Saito, Shoji and Yanagisawa, Ryu and Nakazawa, Yozo},
title = {Ruxolitinib for preventing relapse of Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis},
journal = {Pediatrics International},
year = {2025},
volume = {67},
number = {1},
doi = {10.1111/ped.70032}
}
EUVIMED